204 related articles for article (PubMed ID: 27591334)
1. The complex role of transglutaminase 2 in glioblastoma proliferation.
Gundemir S; Monteagudo A; Akbar A; Keillor JW; Johnson GVW
Neuro Oncol; 2017 Feb; 19(2):208-218. PubMed ID: 27591334
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
5. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
6. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
Liu T; Tee AE; Porro A; Smith SA; Dwarte T; Liu PY; Iraci N; Sekyere E; Haber M; Norris MD; Diolaiti D; Della Valle G; Perini G; Marshall GM
Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18682-7. PubMed ID: 18003922
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy.
Meshram DD; Pike CVS; Coussons PJ
Eur J Pharmacol; 2017 Nov; 815():332-342. PubMed ID: 28943101
[TBL] [Abstract][Full Text] [Related]
8. Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.
Heo JC; Jung TH; Lee S; Kim HY; Choi G; Jung M; Jung D; Lee HK; Lee JO; Park JH; Hwang D; Seol HJ; Cho H
Clin Exp Metastasis; 2016 Jun; 33(5):417-29. PubMed ID: 26957434
[TBL] [Abstract][Full Text] [Related]
9. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
10. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL
Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell death.
Cho SY; Jeong EM; Lee JH; Kim HJ; Lim J; Kim CW; Shin DM; Jeon JH; Choi K; Kim IG
Mol Cells; 2012 Mar; 33(3):235-41. PubMed ID: 22382681
[TBL] [Abstract][Full Text] [Related]
12. Gα(h)/transglutaminase-2 activity is required for maximal activation of adenylylcyclase 8 in human and rat glioma cells.
Obara Y; Yanagihata Y; Abe T; Dafik L; Ishii K; Nakahata N
Cell Signal; 2013 Mar; 25(3):589-97. PubMed ID: 23200849
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase 2 as a therapeutic target for neurological conditions.
Keillor JW; Johnson GVW
Expert Opin Ther Targets; 2021 Sep; 25(9):721-731. PubMed ID: 34607527
[TBL] [Abstract][Full Text] [Related]
14. Inhibition or ablation of transglutaminase 2 impairs astrocyte migration.
Monteagudo A; Ji C; Akbar A; Keillor JW; Johnson GVW
Biochem Biophys Res Commun; 2017 Jan; 482(4):942-947. PubMed ID: 27899316
[TBL] [Abstract][Full Text] [Related]
15. TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells.
Fu J; Yang QY; Sai K; Chen FR; Pang JC; Ng HK; Kwan AL; Chen ZP
Neuro Oncol; 2013 Oct; 15(10):1353-65. PubMed ID: 23877317
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
[TBL] [Abstract][Full Text] [Related]
17. Glycolysis regulated transglutaminase 2 activation in cardiopulmonary fibrogenic remodeling.
Bhedi CD; Nasirova S; Toksoz D; Warburton RR; Morine KJ; Kapur NK; Galper JB; Preston IR; Hill NS; Fanburg BL; Penumatsa KC
FASEB J; 2020 Jan; 34(1):930-944. PubMed ID: 31914588
[TBL] [Abstract][Full Text] [Related]
18. The role of TG2 in regulating S100A4-mediated mammary tumour cell migration.
Wang Z; Griffin M
PLoS One; 2013; 8(3):e57017. PubMed ID: 23469180
[TBL] [Abstract][Full Text] [Related]
19. Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.
Lee J; Yakubov B; Ivan C; Jones DR; Caperell-Grant A; Fishel M; Cardenas H; Matei D
Neoplasia; 2016 Nov; 18(11):689-698. PubMed ID: 27792935
[TBL] [Abstract][Full Text] [Related]
20. A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis.
Wang Z; Perez M; Caja S; Melino G; Johnson TS; Lindfors K; Griffin M
Cell Death Dis; 2013 Sep; 4(9):e808. PubMed ID: 24052076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]